HRP20110697T1 - Uporaba flibanserina za liječenje poremećaja seksualne želje u pre-menopauzi - Google Patents

Uporaba flibanserina za liječenje poremećaja seksualne želje u pre-menopauzi Download PDF

Info

Publication number
HRP20110697T1
HRP20110697T1 HR20110697T HRP20110697T HRP20110697T1 HR P20110697 T1 HRP20110697 T1 HR P20110697T1 HR 20110697 T HR20110697 T HR 20110697T HR P20110697 T HRP20110697 T HR P20110697T HR P20110697 T1 HRP20110697 T1 HR P20110697T1
Authority
HR
Croatia
Prior art keywords
sexual desire
menopause
acid
disorders
flibanserin
Prior art date
Application number
HR20110697T
Other languages
English (en)
Inventor
Pollentier Stephane
Pyke Robert
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37807895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110697(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of HRP20110697T1 publication Critical patent/HRP20110697T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Uporaba, naznačena time, da se koristi flibanserin, po izboru u obliku slobodne baze, farmakološki prihvatljivih kiselinskih adicijskih soli i/ili po izboru u obliku svojih hidrata i/ili solvata za izradu lijeka za liječenje poremećaja seksualne želje u pre-menopauzi kod žena, pri čemu se lijek primjenjuje jednom dnevno uzastopno tijekom određenog vremenskog razdoblja. Patent sadrži još 13 patentnih zahtjeva.

Claims (14)

1. Uporaba, naznačena time, da se koristi flibanserin, po izboru u obliku slobodne baze, farmakološki prihvatljivih kiselinskih adicijskih soli i/ili po izboru u obliku svojih hidrata i/ili solvata za izradu lijeka za liječenje poremećaja seksualne želje u pre-menopauzi kod žena, pri čemu se lijek primjenjuje jednom dnevno uzastopno tijekom određenog vremenskog razdoblja.
2. Uporaba u skladu sa zahtjevom 1, naznačena time, da je poremećaj seksualne želje u pre-menopauzi izabran iz skupine koju čine poremećaj hipoaktivne seksualne želje u pre-menopauzi, poremećaj seksualne averzije u pre-menopauzi, gubitak seksualne želje u pre-menopauzi, manjak seksualne želje u pre-menopauzi, smanjena seksualna želja u pre-menopauzi, inhibirana seksualna želja u pre-menopauzi, gubitak libida u pre-menopauzi, poremećaj libida u pre-menopauzi i frigidnost u pre-menopauzi-
3. Uporaba u skladu sa zahtjevom 1, naznačena time, da poremećaj seksualne želje u pre-menopauzi je poremećaj hipoaktivne seksualne želje u pre-menopauzi.
4. Uporaba u skladu sa zahtjevom 1, 2 ili 3, naznačena time, da poremećaji seksualne želje u pre-menopauzi su cjeloživotnog tipa.
5. Uporaba u skladu sa zahtjevom 1, 2 ili 3, naznačena time, da poremećaji seksualne želje u pre-menopauzi su stečenog tipa.
6. Uporaba u skladu s jednim ili više prethodnih zahtjeva, naznačena time, da poremećaji seksualne želje u pre-menopauzi su općeg subtipa.
7. Uporaba u skladu s jednim ili više prethodnih zahtjeva, naznačena time, da poremećaji seksualne želje u pre-menopauzi su situacijskog subtipa.
8. Uporaba u skladu s jednim ili više prethodnih zahtjeva, naznačena time, da poremećaji seksualne želje u pre-menopauzi su zbog psiholoških faktora.
9. Uporaba u skladu s jednim ili više prethodnih zahtjeva, naznačena time, da poremećaji seksualne želje u pre-menopauzi su zbog organskih faktora.
10. Uporaba u skladu s jednim ili više prethodnih zahtjeva, naznačena time, da poremećaji seksualne želje u pre-menopauzi su zbog spojenih faktora.
11. Uporaba u skladu s jednim ili više prethodnih zahtjeva, naznačena time, da se flibanserin primjenjuje u obliku farmaceutski prihvatljive kiselinske adicijske soli izabrane između soli formiranih pomoću kiselina izabranih iz skupine koju čine sukcinska kiselina, bromidna kiselina, octena kiselina, mravlja kiselina, maleinska kiselina, metansulfonska kiselina, mliječna kiselina, fosforna kiselina, kloridna kiselina, sumporna kiselina, vinska kiselina, limunska kiselina i njihove mješavine.
12. Uporaba u skladu s jednim ili više prethodnih zahtjeva, naznačena time, da se flibanserin primjenjuje u obliku svoje slobodne baze.
13. Uporaba u skladu sa zahtjevom 12, naznačena time, da se flibanserin primjenjuje u obliku polimorfa A slobodne baze koji ima točku tališta na oko 161 °C izmjerenu uporabom DSC.
14. Uporaba u skladu s jednim ili više prethodnih zahtjeva, naznačena time, da se flibanserin primjenjuje isključivo jednom navečer (50 ili 100 mg flibanserina) uzastopno tijekom određenog vremenskog razdoblja.
HR20110697T 2005-11-08 2011-09-29 Uporaba flibanserina za liječenje poremećaja seksualne želje u pre-menopauzi HRP20110697T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73440505P 2005-11-08 2005-11-08
US83101506P 2006-07-14 2006-07-14
PCT/EP2006/068118 WO2007054476A1 (en) 2005-11-08 2006-11-06 Use of flibanserin for the treatment of pre-menopausal sexual desire disorders

Publications (1)

Publication Number Publication Date
HRP20110697T1 true HRP20110697T1 (hr) 2011-10-31

Family

ID=37807895

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110697T HRP20110697T1 (hr) 2005-11-08 2011-09-29 Uporaba flibanserina za liječenje poremećaja seksualne želje u pre-menopauzi

Country Status (30)

Country Link
US (4) US20070105869A1 (hr)
EP (1) EP1948177B1 (hr)
JP (2) JP5386173B2 (hr)
KR (2) KR101436793B1 (hr)
CN (1) CN103251598A (hr)
AR (1) AR059390A1 (hr)
AT (1) ATE521352T1 (hr)
AU (1) AU2006311038B2 (hr)
BR (1) BRPI0618239A8 (hr)
CA (1) CA2626797C (hr)
CY (1) CY1112067T1 (hr)
DK (1) DK1948177T3 (hr)
EA (1) EA014189B1 (hr)
EC (1) ECSP088504A (hr)
ES (1) ES2372421T3 (hr)
HR (1) HRP20110697T1 (hr)
IL (1) IL191245A0 (hr)
MY (1) MY145439A (hr)
NO (1) NO20081527L (hr)
NZ (1) NZ568822A (hr)
PE (1) PE20070800A1 (hr)
PL (1) PL1948177T3 (hr)
PT (1) PT1948177E (hr)
RS (1) RS51961B (hr)
SG (1) SG166820A1 (hr)
SI (1) SI1948177T1 (hr)
TW (1) TWI389689B (hr)
UY (1) UY29899A1 (hr)
WO (1) WO2007054476A1 (hr)
ZA (1) ZA200802542B (hr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
KR20070014184A (ko) * 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び/又は予防用の医薬組成物
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
EP1888071A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of drug-induced sexual dysfunction
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
JP2009513604A (ja) * 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007128802A2 (en) * 2006-05-09 2007-11-15 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090042967A (ko) * 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
AR062321A1 (es) * 2006-08-25 2008-10-29 Boehringer Ingelheim Int Sistema de liberacion controlada y metodo para fabricarlo
EP2097389B1 (en) 2006-12-20 2011-09-14 Boehringer Ingelheim International GmbH Sulfated benzimidazolone derivatives having mixed serotonine receptor affinity
WO2008090742A1 (ja) * 2007-01-23 2008-07-31 National University Corporation Hokkaido University 眼疾患モデル用非ヒト動物
PE20091188A1 (es) * 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
WO2017055935A1 (en) * 2015-09-30 2017-04-06 Symed Labs Limited Amorphous co-precipitates of flibanserin
US20170369475A1 (en) * 2016-06-23 2017-12-28 Sandoz Ag Flibanserin Hydrate
CN115703206A (zh) * 2021-08-09 2023-02-17 环球晶圆股份有限公司 晶棒治具组件与晶棒边抛机台

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3096248A (en) * 1959-04-06 1963-07-02 Rexall Drug & Chemical Company Method of making an encapsulated tablet
US3406178A (en) * 1964-02-04 1968-10-15 Monsanto Chem Australia Ltd Preparation of 2-substituted benzimidazoles
US3362956A (en) * 1965-08-19 1968-01-09 Sterling Drug Inc 1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
US4200641A (en) * 1976-12-21 1980-04-29 Janssen Pharmaceutica, N.V. 1-[(Heterocyclyl)-alkyl]-4-diarylmethoxy piperidine derivatives
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
IT1176613B (it) * 1984-08-14 1987-08-18 Ravizza Spa Derivati piperazinici farmacologicamente attivi e processo per la loro preparazione
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
HUT43600A (en) * 1985-06-22 1987-11-30 Sandoz Ag Process for production of new thiazole derivatives and medical compound containing those
GB8601160D0 (en) * 1986-01-17 1986-02-19 Fujisawa Pharmaceutical Co Heterocyclic compounds
US5036088A (en) * 1986-06-09 1991-07-30 Pfizer Inc. Antiallergy and antiinflammatory agents, compositions and use
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
GB8830312D0 (en) * 1988-12-28 1989-02-22 Lundbeck & Co As H Heterocyclic compounds
US4954503A (en) * 1989-09-11 1990-09-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(1-substituted-4-piperazinyl)-1H-indazoles
NZ241613A (en) * 1991-02-27 1993-06-25 Janssen Pharmaceutica Nv Highlighting intagliations in tablets
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5225417A (en) * 1992-01-21 1993-07-06 G. D. Searle & Co. Opioid agonist compounds
US5492907A (en) * 1992-12-09 1996-02-20 The United States Of America As Represented By The Department Of Health & Human Services Antipsychotic composition and method of treatment
FR2707294B1 (fr) * 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
FR2727682A1 (fr) * 1994-12-02 1996-06-07 Pf Medicament Nouveaux derives de 3,5-dioxo-(2h,4h)-1,2,4-triazines, leur preparation et leur application a titre de medicament
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5883094A (en) * 1995-04-24 1999-03-16 Pfizer Inc. Benzimidazolone derivatives with central dopaminergic activity
US5854290A (en) * 1995-09-21 1998-12-29 Amy F. T. Arnsten Use of guanfacine in the treatment of behavioral disorders
US6083947A (en) * 1996-01-29 2000-07-04 The Regents Of The University Of California Method for treating sexual dysfunctions
US5916916A (en) * 1996-10-10 1999-06-29 Eli Lilly And Company 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
EP0942728A1 (en) * 1996-12-02 1999-09-22 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating sexual dysfunction
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
IL133405A0 (en) * 1997-06-11 2001-04-30 Procter & Gamble Film-coated tablet for improved upper gastrointestinal tract safety
EP0901787B1 (en) * 1997-09-10 2003-05-28 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
JP3724157B2 (ja) * 1997-10-30 2005-12-07 コニカミノルタホールディングス株式会社 映像観察装置
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US20020151543A1 (en) * 1998-05-28 2002-10-17 Sepracor Inc. Compositions and methods employing R (-) fluoxetine and other active ingredients
US6068846A (en) * 1998-08-05 2000-05-30 Melaleuca, Incorporated Methods and materials for treating depression and mood disorder
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
US6680071B1 (en) * 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
IT1313625B1 (it) * 1999-09-22 2002-09-09 Boehringer Ingelheim Italia Derivati benzimidazolonici aventi affinita' mista per i recettori diserotonina e dopamina.
CN1660435A (zh) * 2000-02-24 2005-08-31 法玛西雅厄普约翰美国公司 新的药物联合形式
US6521623B1 (en) * 2000-09-19 2003-02-18 Boehringer Ingelheim Pharma Kg N,N'-disubstituted benzimidazolone derivatives with affinity at the serotonin and dopamine receptors
US6586435B2 (en) * 2000-09-19 2003-07-01 Boehringer Ingelheim Pharma Kg Benzimidazolone derivatives displaying affinity at the serotonin and dopamine receptors
DK1256343T3 (da) * 2001-05-11 2006-10-30 Juergen K Dr Beck Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
PL210224B1 (pl) * 2001-08-02 2011-12-30 Bidachem Spa Krystaliczna odmiana polimorficzna flibanseryny, sposób jej wytwarzania, jej zastosowanie, oraz kompozycje farmaceutyczne ją zawierające
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
UA78974C2 (en) * 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
US20040048877A1 (en) * 2002-05-22 2004-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions containing flibanserin
CA2483597C (en) * 2002-05-22 2010-02-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg New pharmaceutical compositions containing flibanserin polymorph a
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040132697A1 (en) * 2002-11-06 2004-07-08 Pfizer Inc. Treatment of female sexual dysfunction
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
WO2004063864A2 (en) * 2003-01-06 2004-07-29 Laura Berman Method and system for computerized sexual function assessment of female users
US20050004105A1 (en) * 2003-01-29 2005-01-06 Emer Leahy Treatment for a attention-deficit hyperactivity disorder
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
US20050065158A1 (en) * 2003-07-16 2005-03-24 Pfizer Inc. Treatment of sexual dysfunction
KR20070014184A (ko) * 2004-04-22 2007-01-31 베링거 인겔하임 인터내셔날 게엠베하 성기능 장애 치료용 신규 약제학적 조성물 ⅱ
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
US20060014757A1 (en) * 2004-07-14 2006-01-19 Boehringer Ingelheim Pharmaceuticals Method for the treatment of anorexia nervosa
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
WO2006096435A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
JP2008531714A (ja) * 2005-03-04 2008-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 不安障害の治療用及び/又は予防用の医薬組成物
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
US20060258640A1 (en) * 2005-05-13 2006-11-16 Boehringer Ingelheim International Gmbh Use of Flibanserin in the treatment of chronic pain
EP1888071A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of drug-induced sexual dysfunction
EP1888070A1 (en) * 2005-05-19 2008-02-20 Boehringer Ingelheim International GmbH Method for the treatment of sexual dysfunctions due to medical conditions
US8227476B2 (en) * 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
JP2009513604A (ja) * 2005-10-29 2009-04-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 月経前障害及び他の女性の性的障害治療用のベンゾイミダゾロン誘導体
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20090023712A1 (en) * 2006-02-18 2009-01-22 Boehringer Ingelheim International Gmbh Pharmaceutical Compositions for the Treatment of Attention Deficit Hyperactivity Disorder Comprising Flibanserin
US20090176698A1 (en) * 2006-02-20 2009-07-09 Boehringer Ingelheim International Gmbh Benzimidazolone Derivatives for the Treatment of Urinary Incontinence
US20090247546A1 (en) * 2006-02-28 2009-10-01 Boehringer Ingelheim International Gmbh Treatment of Prevention of Valvular Heart Disease with Flibanserin
WO2008000760A1 (en) * 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
US20090318469A1 (en) * 2006-07-14 2009-12-24 Boehringer Ingelheim International Gmbh Use of Flibanserin for the Treatment of Sexual Disorders in Females
EP2043649A2 (en) * 2006-07-14 2009-04-08 Boehringer Ingelheim International GmbH Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
KR20090042967A (ko) * 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법

Also Published As

Publication number Publication date
IL191245A0 (en) 2009-08-03
ZA200802542B (en) 2009-01-28
NO20081527L (no) 2008-07-31
ECSP088504A (es) 2008-07-30
JP5386173B2 (ja) 2014-01-15
EA200801138A1 (ru) 2008-10-30
KR20080070059A (ko) 2008-07-29
US20150366862A1 (en) 2015-12-24
PT1948177E (pt) 2011-09-12
SG166820A1 (en) 2010-12-29
TW200803857A (en) 2008-01-16
AU2006311038A1 (en) 2007-05-18
BRPI0618239A8 (pt) 2018-05-15
NZ568822A (en) 2011-09-30
US20070105869A1 (en) 2007-05-10
WO2007054476A1 (en) 2007-05-18
ATE521352T1 (de) 2011-09-15
AR059390A1 (es) 2008-04-09
KR101436793B1 (ko) 2014-09-03
CN103251598A (zh) 2013-08-21
DK1948177T3 (da) 2011-11-21
ES2372421T3 (es) 2012-01-19
CA2626797A1 (en) 2007-05-18
UY29899A1 (es) 2007-06-29
CA2626797C (en) 2014-01-21
PL1948177T3 (pl) 2012-01-31
US20130225604A1 (en) 2013-08-29
BRPI0618239A2 (pt) 2011-08-23
CY1112067T1 (el) 2015-11-04
EA014189B1 (ru) 2010-10-29
SI1948177T1 (sl) 2011-12-30
MY145439A (en) 2012-02-15
AU2006311038B2 (en) 2012-09-20
EP1948177A1 (en) 2008-07-30
JP2013177412A (ja) 2013-09-09
EP1948177B1 (en) 2011-08-24
TWI389689B (zh) 2013-03-21
US20140329827A1 (en) 2014-11-06
RS51961B (en) 2012-02-29
KR20140003659A (ko) 2014-01-09
JP2009514929A (ja) 2009-04-09
PE20070800A1 (es) 2007-08-13

Similar Documents

Publication Publication Date Title
HRP20110697T1 (hr) Uporaba flibanserina za liječenje poremećaja seksualne želje u pre-menopauzi
AU2007247094B2 (en) Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders
US20060264511A1 (en) Method for the treatment of drug-induced sexual dysfunction
RU2015110470A (ru) Фармацевтическая композиция для местного нанесения, включающая тенофовир, антибактериальный агент и необязательно циклопирокс
RU2018133298A (ru) Способы применения агонистов fxr
US20060211685A1 (en) Pharmaceutical compositions for the treatment and/or prevention of depression
JP2009536176A5 (hr)
HRP20150838T1 (hr) Sastavi koji sadrže modulatore receptora sfingozin 1 fosfata (s1p)
HRP20201405T1 (hr) Derivat 5-etil-4-metil-pirazol-3-karboksamida, koji djeluje kao agonist taar-a
CA2608713A1 (en) Method for the treatment of sexual dysfunctions due to medical conditions
JP2010530376A5 (hr)
JP2009527525A (ja) 尿失禁治療用のベンゾイミダゾロン誘導体
RU2011137131A (ru) Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха
US20220347157A1 (en) Sustained release pharmaceutical compositions comprising (1r, 5s)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane
CO5060477A1 (es) Forma de dosificacion de nefazodona
JP2005516904A5 (hr)
JP2010522714A (ja) 新規な医薬組成物
RU2013153140A (ru) Новая ассоциация между 4-{3-[цис-гексагидроциклопента[c] пиррол-2 (1н )- ил] пропокси} бензамидом и ингибитором ацетилхолинэстеразы и фармацевтические композиции, которые ее содержат
EP4306113A3 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
MX2022012898A (es) Ecomposición farmacéutica para administración oral que comprende derivado de aminopirimidina o sal, hidrato o solvato farmacéuticamente aceptable de esta.
JP2018039810A5 (hr)
HRP20201412T1 (hr) Trostruka kombinacija čistih antagonista receptora 5-ht6, inhibitora acetilkolinesteraze i antagonista receptora nmda
MX2021015827A (es) Antagonista de neurokinin -1.
HRP20120344T1 (hr) N-(2-hidroksietil)-n-metil-4-(kinolin-8-il(1-(tiazol-4-ilmetil) piperidin-4-iliden)metil)benzamid, postupak njegovog dobivanja kao i njegova uporaba za liječenje bola, tjeskobe i depresije
HRP20130225T1 (hr) Formulacija s odgođenim otpuštanjem koja sadrži 3-(2-dimetilaminometilcikloheksil) fenol